Ocular Therapeutix, Inc., commonly referred to as Ocular Therapeutix, is a pioneering biopharmaceutical company headquartered in the United States. Founded in 2014, the company focuses on the development and commercialisation of innovative therapies for ocular diseases and conditions. With a strong presence in the ophthalmic industry, Ocular Therapeutix has made significant strides in creating unique drug delivery systems that enhance patient outcomes. The company’s flagship products include Dextenza, a sustained-release dexamethasone insert for post-surgical inflammation, and OTX-TP, a novel treatment for glaucoma. These offerings distinguish Ocular Therapeutix in the market, showcasing its commitment to advancing ocular health. Recognised for its innovative approach, Ocular Therapeutix continues to solidify its position as a leader in the ophthalmic therapeutics sector, driving forward with a robust pipeline of products aimed at addressing unmet medical needs.
How does Ocular Therapeutix, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Ocular Therapeutix, Inc.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ocular Therapeutix, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Ocular Therapeutix may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the company does not inherit emissions data from a parent organisation, it operates independently regarding its climate impact reporting. Without specific emissions figures or reduction initiatives, Ocular Therapeutix's climate commitments remain unclear within the broader context of industry standards for sustainability and carbon management.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ocular Therapeutix, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.